EyePoint, Inc. (EYPT)
| Market Cap | 270.71M -70.6% |
| Revenue (ttm) | 2.79M -94.6% |
| Net Income | -306.64M |
| EPS | -3.76 |
| Shares Out | 86.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,835,642 |
| Open | 3.020 |
| Previous Close | 3.010 |
| Day's Range | 3.009 - 3.175 |
| 52-Week Range | 2.930 - 19.110 |
| Beta | 1.68 |
| Analysts | Buy |
| Price Target | 25.91 (+725.16%) |
| Est. Earnings | Nov 4, 2026 |
About EYPT
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet ... [Read more]
Financial Performance
In 2025, EyePoint's revenue was $31.37 million, a decrease of -27.50% compared to the previous year's $43.27 million. Losses were -$231.96 million, 77.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for EYPT stock is "Buy." The 12-month stock price target is $25.91, which is an increase of 725.16% from the latest price.
News
These beaten-down stocks could bounce back in January, if history is any guide
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with seriou...
EyePoint Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Recent phase III data showed strong secondary outcomes and safety for a novel wet AMD therapy, despite missing the primary endpoint due to unusual control arm results. A second pivotal trial, LUCIA, will address these findings with data expected in Q4 2026, supporting a potential NDA in 2027.
EyePoint Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Strong secondary outcomes in the LUGANO trial showed reduced treatment burden and good safety, despite missing the primary endpoint due to an unusual control arm result. The upcoming LUCIA trial will address these findings with more robust analyses, and positive results are expected to support regulatory approval.
EyePoint Transcript: Citigroup’s Biopharma Back to School Summit 2026
DURAVYU's phase III program in wet AMD and DME shows strong safety, reduced injection burden, and promising secondary endpoints, despite a primary endpoint miss in LUGANO attributed to randomization. LUCIA results are expected in Q4, with regulatory submission planned for the first half of next year.
EyePoint Slides: Corporate presentation
EyePoint has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with ...
EyePoint downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded EyePoint (EYPT) to Hold from Buy with a price target of $4, down from $20. The company’s first Phase III wet age-related macular degeneration study failed, the…
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $EYPT--EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law.
EyePoint price target lowered to $20 from $43 at Jones
Jones lowered the firm’s price target on EyePoint (EYPT) to $20 from $43 and keeps a Buy rating on the shares. The company is confident the LUGANO stdudy primary miss…
EyePoint downgraded to Neutral from Buy at Chardan
Chardan downgraded EyePoint (EYPT) to Neutral from Buy with a price target of $5, down from $65. he company’s LUGANO study missing its Phase 3 non-inferiority primary endpoint, and Chardan…
EyePoint downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded EyePoint (EYPT) to Neutral from Buy without a price target after the failed Phase 3 LUGANO trial of Duravyu in wet age-related macular degeneration. If such an…
EyePoint price target lowered to $17 from $35 at Citi
Citi lowered the firm’s price target on EyePoint (EYPT) to $17 from $35 and keeps a Buy rating on the shares. The firm sees greater risk for the LUCIA stud…
EyePoint downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital last night downgraded EyePoint (EYPT) to Sector Perform from Outperform with a price target of $5, down from $37. The LUGANO study missed its primary non-inferiority endpoint, which…
EyePoint downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded EyePoint (EYPT) to Sector Perform from Outperform with a price target of $5, down from $37.
Clear Street sees less competition for Ocular after EyePoint miss
Clear Street reiterates a Buy rating on Ocular Therapeutix (OCUL) (OCLX) after its competitor EyePoint (EYPT) reported the LUGANO study did not meet its primary endpoint. The trial miss potentially…
Laidlaw trims EyePoint target, still sees high chance of approval
Laidlaw analyst Yale Jen lowered the firm’s price target on EyePoint (EYPT) to $48 from $50 and keeps a Buy rating on the shares. Although the primary endpoint miss in…
Laidlaw trims EyePoint target, still sees high change of approval
Laidlaw analyst Yale Jen lowered the firm’s price target on EyePoint (EYPT) to $48 from $50 and keeps a Buy rating on the shares. Although the primary endpoint miss in…
B. Riley views EyePoint study miss as positive for 4D Molecular
B. Riley analyst Mayank Mamtani reiterates a Buy rating on 4D Molecular (FDMT) with a $37 price target after EyePoint (EYPT) reported its Phase 3 clinical trial for Duravyu for…
EyePoint price target lowered to $8 from $30 at Jefferies
Jefferies lowered the firm’s price target on EyePoint (EYPT) to $8 from $30 and keeps a Buy rating on the shares. The firm views the LUGANO data as mixed. The…
Why Is EyePoint Pharmaceuticals (EYPT) Stock Down 69% Today?
EyePoint Pharmaceuticals stock was down 69.19% on Monday after a clinical trial update failed to impress investors.
EyePoint downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded EyePoint (EYPT) to Neutral from Overweight.
EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction.
Duravyu, EyePoint's candidate for wet age-related macular degeneration, misses the mark, but muddled trial data may be to blame.
EyePoint downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald downgraded EyePoint (EYPT) to Neutral from Overweight without a price target after the company’s first pivotal Phase 3 clinical trial for Duravyu for the treatment of wet age-related...
EyePoint Transcript: Study result
Corrected summary: The LUGANO phase III trial for DURAVYU in wet AMD missed the primary non-inferiority endpoint due to nine patients with severe vision loss from non-wet AMD causes, but excluding these, non-inferiority was achieved. DURAVYU showed a 42% reduction in treatment burden, strong anatomic control, and a favorable safety profile.